AIM ImmunoTech Inc. has received authorizations from the Competent Authority and Ethics Board in the Netherlands to begin a Phase 1b/2 study evaluating Ampligen, its TLR-3 agonist, in combination with durvalumab, a checkpoint inhibitor. The study aims to explore the safety and clinical benefit of this combination therapy in patients with metastatic pancreatic ductal adenocarcinoma. Patient enrollment is expected to start before the end of 2023.
Ampligen has shown potential synergies with checkpoint inhibitors, which could lead to increased survival rates and efficacy in cancer treatment. AIM ImmunoTech is focused on developing Ampligen as a novel therapeutic for locally advanced pancreatic cancer and metastatic pancreatic cancer.
The required approvals for the study were obtained from the Central Committee on Research Involving Human Subjects and the Medical Ethics Review Committee Erasmus MC in the Netherlands. The Phase 1b/2 study will be conducted at Erasmus Medical Center under an external sponsored